Duke Blood Cancer Center

Durham, North Carolina 27705

3 studies enrolling now · 5 studies all time

What they study most

AML With Mutated NPM1, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, Hematologic Malignancy, KMT2Ar, Large B-cell Lymphoma, Mixed Lineage Leukemia Gene Mutation, Myeloid Sarcoma, NPM1 Mutation, Nucleophosmin 1-mutated Acute Myeloid Leukemia, Refractory AML

Studies at this site

• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL — Recruiting now
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — Recruiting now
• VitalTraq for the Detection of CRS — Completed
• Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis — Available (expanded access)
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated — Stopped early